Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Companion Diagnostics Spark Pharma Deals - But Still Mostly For Cancer

Executive Summary

An inaugural review of the diagnostics sector newly published by PricewaterhouseCoopers contends that growing interest in personalized medicine is a key factor driving partnering deals between pharmaceutical companies and diagnostics developers
Advertisement

Related Content

Companion Diagnostics Move Toward Mainstream Drug Development
Companion Diagnostics Move Toward Mainstream Drug Development
Biomarkers: Venture Capitalists Press FDA For Better Development Incentives
Biomarkers: Venture Capitalists Press FDA For Better Development Incentives
KRAS Testing Gets On Label Of EGFr Products; Will Tests Get To Clinic Soon?
Companion Dx Pioneers Test Variety Of Business Models
Drug, Diagnostic Firms Should Partner, Not Merge, To Personalize Medicine
Novartis Pharma To Add Diagnostics Unit In 2009
Problems With Biomarkers: A Tale of Three Drugs
AstraZeneca's Iressa Problem

Topics

Advertisement
UsernamePublicRestriction

Register

PS051476

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel